{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:15:24Z","timestamp":1780704924929,"version":"3.54.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Familial partial lipodystrophy type 3 (FPLD3) is an autosomal dominant disease. Patients typically present with loss of adipose tissue and metabolic complications. Here, we reported a Chinese FPLD3 patient with a novel <jats:italic>PPARG<\/jats:italic> gene mutation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A 16-year-old female patient and her relatives were assessed by detailed clinical and biochemical examinations. Sequencing was performed by using the extracted DNA. Moreover, we identified FPLD3 patients from previous studies, and according to the protein region affected by the gene mutation. We divided the patients into the DNA-binding domain (DBD) group or the ligand-binding domain (LBD) group, and compared the clinical features between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified a novel gene mutation affecting the LBD of PPAR\u03b3 c.929T\u2009&amp;gt;\u2009C (p.F310S). This mutation leads to the substitution of a phenylalanine by a serine. In our case, subcutaneous fat was significantly diminished in her face, hips and limbs. The patient was also presented with insulin resistance, diabetes mellitus, hypertriglyceridemia, fatty liver, liver dysfunction, albuminuria and diabetic peripheral neuropathy. After literature review, a total of 58 FPLD3 patients were identified and we found no difference in clinical features between the DBD group and LBD group (all P &amp;gt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A Chinese FPLD3 patient with a novel <jats:italic>PPARG<\/jats:italic> gene mutation is described. Our case emphasized the importance of physical examination and genetic testing in young patients with severe metabolic syndromes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.830708","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T03:51:50Z","timestamp":1648612310000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Case Report: A New Peroxisome Proliferator-Activated Receptor Gamma Mutation Causes Familial Partial Lipodystrophy Type 3 in a Chinese Patient"],"prefix":"10.3389","volume":"13","author":[{"given":"Xi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S206053","article-title":"Familial Partial Lipodystrophy (FPLD): Recent Insights","volume":"13","author":"Bagias","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00032.2020","article-title":"Lipodistrophy: A Paradigm for Understanding the Consequences of \"Overloading\" Adipose Tissue","volume":"101","author":"Lim","year":"2021","journal-title":"Physiol Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12837","article-title":"Novel Peroxisome Proliferator-Activated Receptor Gamma Mutation in a Family With Familial Partial Lipodystrophy Type 3","volume":"84","author":"Miehle","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3700","article-title":"Prospective Functional Classification of All Possible Missense Variants in PPARG","volume":"48","author":"Majithia","year":"2016","journal-title":"Nat Genet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.tem.2014.04.001","article-title":"PPARgamma and the Global Map of Adipogenesis and Beyond","volume":"25","author":"Lefterova","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.2001.81.3.1269","article-title":"Nuclear Hormone Receptors and Gene Expression","volume":"81","author":"Aranda","year":"2001","journal-title":"Physiol Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4158\/endp.19.1.v767575m65p5mr06","article-title":"The Clinical Approach to the Detection of Lipodystrophy - An AACE Consensus Statement","volume":"19","author":"Handelsman","year":"2013","journal-title":"Endocr Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/47254","article-title":"Dominant Negative Mutations in Human PPARgamma Associated With Severe Insulin Resistance, Diabetes Mellitus and Hypertension","volume":"402","author":"Barroso","year":"1999","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1136\/jmg.2007.050567","article-title":"New PPARG Mutation Leads to Lipodystrophy and Loss of Protein Function That is Partially Restored by a Synthetic Ligand","volume":"44","author":"Ludtke","year":"2007","journal-title":"J Med Genet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2006.00674.x","article-title":"A Frameshift Mutation in Peroxisome-Proliferator-Activated Receptor-Gamma in Familial Partial Lipodystrophy Subtype 3 (FPLD3; MIM 604367)","volume":"70","author":"Hegele","year":"2006","journal-title":"Clin Genet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.1.8290","article-title":"A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor-Gamma Gene in a Patient With Familial Partial Lipodystrophy","volume":"87","author":"Agarwal","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2014.06.006","article-title":"Biallelic Mutations at PPARG Cause a Congenital, Generalized Lipodystrophy Similar to the Berardinelli-Seip Syndrome","volume":"57","author":"Dyment","year":"2014","journal-title":"Eur J Med Genet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104017","article-title":"A Mosaic Activating Mutation in AKT1 Associated With the Proteus Syndrome","volume":"365","author":"Lindhurst","year":"2011","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12881-017-0484-6","article-title":"HDR Syndrome With a Novel Mutation in GATA3 Mimicking a Congenital X-Linked Stapes Gusher: A Case Report","volume":"18","author":"Yang","year":"2017","journal-title":"BMC Med Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/db17-1236","article-title":"A Pharmacogenetic Approach to the Treatment of Patients With PPARG Mutations","volume":"67","author":"Agostini","year":"2018","journal-title":"Diabetes"},{"key":"B16","doi-asserted-by":"publisher","first-page":"868190","DOI":"10.1101\/868190","article-title":"PPAR\u03b3 is a Tumor Suppressor In Basal Bladder Tumors Offering New Potential Therapeutic Opportunities","author":"Coutos-Th\u00e9venot","year":"2019","journal-title":"bioRxiv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2624","article-title":"Peroxisome Proliferator-Activated Receptor-Gamma C190S Mutation Causes Partial Lipodystrophy","volume":"92","author":"Ludtke","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P025437","article-title":"Clinical and Molecular Characterization of a Severe Form of Partial Lipodystrophy Expanding the Phenotype of PPARgamma Deficiency","volume":"53","author":"Campeau","year":"2012","journal-title":"J Lipid Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.12.005","article-title":"Natural Helix 9 Mutants of PPARgamma Differently Affect Its Transcriptional Activity","volume":"20","author":"Broekema","year":"2019","journal-title":"Mol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01462-y","article-title":"The Novel Loss of Function\u00a0Ile354Val Mutation in PPARG Causes Familial Partial Lipodystrophy","volume":"57","author":"Padova","year":"2020","journal-title":"Acta Diabetol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-020-2184-2","article-title":"Effects of PPAR-Gamma in the Myocardium on the Development of Ventricular Septation","volume":"40","author":"Zhou","year":"2020","journal-title":"Curr Med Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80209-9","article-title":"PPARG Is Required for Placental, Cardiac, and Adipose Tissue Development","volume":"4","author":"Barak","year":"1999","journal-title":"Mol Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.7812\/TPP\/09-052","article-title":"Thiazolidinediones: A 2010 Perspective","volume":"14","author":"Krishnaswami","year":"2010","journal-title":"Perm J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000179226.34112.6d","article-title":"Cardiomyocyte-Specific Knockout and Agonist of Peroxisome Proliferator-Activated Receptor-Gamma Both Induce Cardiac Hypertrophy in Mice","volume":"97","author":"Duan","year":"2005","journal-title":"Circ Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2007.06.027","article-title":"Cardiac Peroxisome Proliferator-Activated Receptor Gamma is Essential in Protecting Cardiomyocytes From Oxidative Damage","volume":"76","author":"Ding","year":"2007","journal-title":"Cardiovasc Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-7-3","article-title":"Peroxisomal Proliferator Activated Receptor-Gamma Deficiency in a Canadian Kindred With Familial Partial Lipodystrophy Type 3 (FPLD3)","volume":"7","author":"Francis","year":"2006","journal-title":"BMC Med Genet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/153537020422901107","article-title":"Role of Estrogens in Adipocyte Development and Function","volume":"229","author":"Cooke","year":"2004","journal-title":"Exp Biol Med (Maywood)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/2042-6410-3-13","article-title":"Sex Differences in Human Adipose Tissues - the Biology of Pear Shape","volume":"3","author":"Karastergiou","year":"2012","journal-title":"Biol Sex Differ"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000108","article-title":"Metabolic Actions of Estrogen Receptor Beta (ERbeta) are Mediated by a Negative Cross-Talk With PPARgamma","volume":"4","author":"Foryst-Ludwig","year":"2008","journal-title":"PloS Genet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2019.02.002","article-title":"Gene-Gene and Gene-Environment Interactions in Lipodystrophy: Lessons Learned From Natural PPARgamma Mutants","volume":"1864","author":"Broekema","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00321.2003","article-title":"Evidence for Functional Estrogen Receptors Alpha and Beta in Human Adipose Cells: Regional Specificities and Regulation by Estrogens","volume":"286","author":"Dieudonne","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-4-200008150-00009","article-title":"Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes","volume":"133","author":"Arioglu","year":"2000","journal-title":"Ann Intern Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.4.910","article-title":"Human Metabolic Syndrome Resulting From Dominant-Negative Mutations in the Nuclear Receptor Peroxisome Proliferator-Activated Receptor-Gamma","volume":"52","author":"Savage","year":"2003","journal-title":"Diabetes"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3645","article-title":"Local Application of Low-Dose Insulin in Improving Wound Healing After Deep Burn Surgery","volume":"12","author":"Wang","year":"2016","journal-title":"Exp Ther Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00682.x","article-title":"Correction of Facial Lipoatrophy Using Autologous Fat Transplants in HIV-Infected Adolescents","volume":"10","author":"Dollfus","year":"2009","journal-title":"HIV Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.830708\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T03:51:53Z","timestamp":1648612313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.830708\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":35,"alternative-id":["10.3389\/fendo.2022.830708"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.830708","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]},"article-number":"830708"}}